Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chiesi Farmaceutici
Pharma
Chiesi grows rare disease ambitions with $1.9B KalVista buyout
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
Fraiser Kansteiner
Apr 29, 2026 10:01am
FDA blesses Chiesi’s Filsuvez for rare skin disease EB
Dec 20, 2023 8:20am
Europe signs off on Protalix, Chiesi's Fabry disease treatment
May 5, 2023 2:40pm
5 years after European nod, Chiesi wins FDA approval for Lamzede
Feb 17, 2023 10:09am
After Amryt buy, Chiesi names Baxter vet Accogli its new CEO
Jan 30, 2023 2:00am
JPM23, Day 1: BMS, Regeneron, BioMarin and more
Jan 9, 2023 7:12pm
